TareBio GTM brain

category

market profile

• text: The company's reported platform uses immune responses to reverse-engineer vaccine antigens; its reported efficacy evidence is in mice, not patients.
• text: Personalized cancer vaccines are a competitive field with clinical-stage programs from Moderna and BioNTech.

personas

• title: Head of immuno-oncology research
  pains:

  • Selecting antigens that actually drive useful immune responses in heterogeneous tumors
  • Determining whether preclinical immune responses translate to patients
• title: Vaccine discovery and translational research lead
  pains:

  • Prioritizing disease-relevant antigens from limited immune samples
  • Rebuilding discovery workflows for each indication
• title: Biopharma business development lead
  pains:

  • Evaluating early platforms before human validation
  • Assessing intellectual property, manufacturing feasibility and collaboration economics

icp

• text: Potential partners are biopharma R&D groups with therapeutic cancer vaccine programs; buyer size and signed customers are not publicly established.
• text: Academic or translational immunology groups with access to disease-reactive immune samples are plausible research collaborators, rather than confirmed customers.

message pillars

• text: Broad vaccine platform ambition.
• text: Cancer is an explicit initial disease area.
• text: Infections are also in the stated scope.

objections

• objection: Has it worked in people?
  response: The public account describes mouse evidence; request data, reproducibility and the human translation plan.
• objection: Can the platform generalize to my indication?
  response: Request indication-specific validation and details of the immune samples required. Broad coverage is an ambition.
• objection: Can a personalized vaccine be manufactured and approved at scale?
  response: Discuss process, quality controls and regulatory plans with the team; public detail is limited.

competitors

• name: Moderna
  why: Develops individualized cancer vaccines with Merck, a competing approach to cancer immunotherapy.
• name: BioNTech
  why: Develops personalized cancer immunotherapies using a different vaccine platform.
• name: Transgene
  why: Develops personalized neoantigen vaccines for cancer.

influencers

• name: Eta Atolia
  url: https://fundraisingfox.com/people/eta-atolia
  why: Founder and CEO; relevant voice for platform and partnership updates.

keywords

• personalized cancer vaccines
• immune guided antigen discovery
• therapeutic cancer vaccine platform
• neoantigen vaccine development
• infectious disease vaccine discovery
• immuno-oncology research partnerships

voice

• Concise
• Ambitious
• Science-oriented

signals

• text: A biopharma group is expanding personalized cancer vaccine R&D or seeking new antigen discovery collaborators.
• text: A research group has disease-reactive immune samples and a program to identify vaccine antigens.

pricing

motion

confidence

Founders

• name: Eta Atolia
  title: Founder/CEO
  role: CEO
  bio: Founder & CEO, TareBio (YC S26). MD-PhD from UCLA-Caltech, where she built a novel platform that develops vaccines for any cancer or infection in weeks, funded by the Gates Foundation. BS in Biology from MIT. Conducted research at the Koch Institute, Harvard Medical School, and the Weizmann. Select Awards: UCLA MD-PhD Merit Scholar, UCLA TDG Senior Fellow, MIT iGEM Gold Medal, MIT IDEAs winner, MIT Dean Advisory Group, WhiteHouse Science Fair, Bessie Lawrence Scholar, Intel STS Finalist